Ana Moreno
Founder & Chief Executive Officer Navega Therapeutics
Ana Moreno is the founder and CEO of Navega Therapeutics. She obtained her Ph.D. from the Bioengineering Department at UCSD , where she spent the last four years developing the platform that enables Navega’s innovative approach.
Seminars
Thursday 28th January 2027
Epigenetic Gene Regulation of NaV1.7: Reprogramming Pain Signalling for Durable Relief in Chronic Pain
1:30 pm
- Harnessing zinc-finger epigenome regulation technology to selectively downregulate SCN9A, the gene encoding NaV1.7, a genetically validated driver of pain signalling
- Developing NT-Z001 as an AAV-delivered epigenetic therapy designed to provide long-lasting relief from neuropathic and inflammatory pain following a single administration
- Reviewing preclinical evidence demonstrating durable pain reduction without the addiction risks associated with opioids
- Exploring how epigenetic therapies could shift chronic pain treatment from symptom management to long-term modulation of pain biology
